ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
Roivant Sciences Ltd.
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$34.70+1.17 (+3.49%)
Close on Oct 19, 2026
- Market cap
- $25.01B
- P/E (TTM)
- –
- Dividend yield
- –
Roivant Sciences Ltd. revenue by segment
By business segment
By product or service
| Revenue | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | TTM Q4 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License, Milestone and Other Revenue [Member] | – | – | – | – | – | – | $81.54M | $49.74M | $53.84M | $45.17M | $34.06M | $33.27M | – | – |
| Product revenue, net | – | – | – | – | – | – | $76.77M | $75.06M | $69.41M | $57.98M | $44.53M | $28.01M | – | – |
By region
From the segment and revenue-disaggregation notes of Roivant Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.